-
1 Comment
Dr. Reddy's Laboratories Limited is currently in a long term uptrend where the price is trading 9.8% above its 200 day moving average.
From a valuation standpoint, the stock is 14.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.
Dr. Reddy's Laboratories Limited's total revenue rose by 12.1% to $49B since the same quarter in the previous year.
Its net income has increased by 103.7% to $198M since the same quarter in the previous year.
Finally, its free cash flow fell by 76.5% to $1B since the same quarter in the previous year.
Based on the above factors, Dr. Reddy's Laboratories Limited gets an overall score of 4/5.
ISIN | INE089A01023 |
---|---|
Exchange | NSE |
CurrencyCode | INR |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Market Cap | 987B |
---|---|
PE Ratio | 18.42 |
Target Price | 1321.8 |
Beta | 0.48 |
Dividend Yield | 0.7% |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for DRREDDY.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025